Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. Issue 3 (20th December 2016)

• Record Type: Journal Article
• Authors: Du, Xiao‐Jing; Chen, Lei; Li, Wen‐Fei; Tang, Ling‐Long; Mao, Yan‐Ping; Guo, Rui; Sun, Ying; Lin, Ai‐Hua; Ma, Jun
• Is Part Of: Head & neck. Volume 39:Issue 3(2017)
• Page Start: 492
• Page End: 497
• Publication Date: 2016-12-20
• Subjects: uric acid -- nasopharyngeal carcinoma -- prognosis -- metastasis -- intensity‐modulated radiotherapy; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24631
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The purpose of this study was to determine the predictive value of pretreatment serum uric acid (SUA) for metastasis in locally advanced nasopharyngeal carcinoma (NPC) treated with intensity‐modulated radiotherapy. Methods: This retrospective study examined 1063 patients with locally advanced NPC. Multivariate survival analysis was used. Results: High pretreatment SUA level (>353.4 μmol/L) independently predicted distant metastasis‐free survival ( p = .013) and was associated with high white blood cell ( p = .005), lymphocyte counts ( p < .001), and male sex ( p < 0.001). In addition, SUA levels were significantly elevated in patients with T1 to T3 classification ( p = .042). For patients with subsequent lung metastases after treatment, markedly higher pretreatment SUA levels were detected compared with patients who had other distant metastases ( p =.012) and patients without distant metastasis ( p = .024). Conclusion: Pretreatment SUA may be a useful biomarker for evaluating treatment options for patients with locally advanced NPC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 492–497, 2017